Amneal Pharmaceuticals

UBS set a USD 25.00 target for Amneal Pharmaceuticals stock on October 1, while second-quarter revenue reached USD 796.2 million. Adjusted EPS beat consensus.

The analyst fair value estimate for Amneal Pharmaceuticals has shifted from US$22.00 to about US$22.71 per share, reflecting updated price targets within the US$20 to US$27 range that are guiding much of the current discussion. Analysts are tying these ta

ALPHA Overview of TechnologyWhat is SciTech at Amneal Pharmaceuticals?Formulation technology that 'redesigns' complex pharmaceuticalsTo understand the science and technology of Amneal Pharmaceuticals, it is important not to view the company merely as a ge

- Expands complex injectables portfolio with important long-acting oncology treatment - Immediate commercial launch supported by in-house production BRIDGEWATER, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE)

Detailed price information for Amneal Pharmaceuticals Inc (AMRX-Q) from The Globe and Mail including charting and trades.

On August 10, Amneal Pharmaceuticals (NASDAQ:AMRX) completed its acquisition of Kashiv BioSciences, a deal that co-CEO Chirag Patel called a pivotal step in the company's push to become America's top Affordable Medicines company. The combination pairs Kas

Amneal Pharmaceuticals announced that it has entered into a definitive agreement to acquire Kashiv BioSciences, a move aimed at creating a fully integrated global biosimilars platform and expanding access to affordable biologic medicines.

The post We believe everyone deserves access to medicine appeared first on Amneal Pharmaceuticals.